CN115427052A - 线粒体加强疗法 - Google Patents

线粒体加强疗法 Download PDF

Info

Publication number
CN115427052A
CN115427052A CN202180024268.7A CN202180024268A CN115427052A CN 115427052 A CN115427052 A CN 115427052A CN 202180024268 A CN202180024268 A CN 202180024268A CN 115427052 A CN115427052 A CN 115427052A
Authority
CN
China
Prior art keywords
cells
mitochondria
mitochondrial
cell
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180024268.7A
Other languages
English (en)
Chinese (zh)
Inventor
N·伊夫吉-奥哈纳
N·谢尔
M·布鲁姆金
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minovia Treatment
Original Assignee
Minovia Treatment
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minovia Treatment filed Critical Minovia Treatment
Publication of CN115427052A publication Critical patent/CN115427052A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN202180024268.7A 2020-03-31 2021-03-29 线粒体加强疗法 Pending CN115427052A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063003174P 2020-03-31 2020-03-31
US63/003,174 2020-03-31
US202063118569P 2020-11-25 2020-11-25
US63/118,569 2020-11-25
PCT/IL2021/050349 WO2021199032A1 (en) 2020-03-31 2021-03-29 Mitochondrial augmentation therapy

Publications (1)

Publication Number Publication Date
CN115427052A true CN115427052A (zh) 2022-12-02

Family

ID=77928517

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180024268.7A Pending CN115427052A (zh) 2020-03-31 2021-03-29 线粒体加强疗法

Country Status (12)

Country Link
US (1) US20230338427A1 (https=)
EP (1) EP4125959A4 (https=)
JP (1) JP7825866B2 (https=)
KR (1) KR20220161326A (https=)
CN (1) CN115427052A (https=)
AU (1) AU2021248780A1 (https=)
BR (1) BR112022019432A2 (https=)
CA (1) CA3173425A1 (https=)
CO (1) CO2022013978A2 (https=)
IL (1) IL296786A (https=)
MX (1) MX2022012233A (https=)
WO (1) WO2021199032A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12329781B2 (en) 2018-07-22 2025-06-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
JP2021531288A (ja) 2018-07-22 2021-11-18 ミノヴィア セラピューティクス リミテッド 眼疾患のミトコンドリア増強療法
WO2020021536A1 (en) 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
JP7524157B2 (ja) 2018-07-22 2024-07-29 ミノヴィア セラピューティクス リミテッド 脳疾患のミトコンドリア増強療法
CA3172402A1 (en) 2020-03-31 2021-10-07 Minovia Therapeutics Ltd. Mitochondria-enriched genetically engineered cells and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL299482B2 (en) * 2015-02-26 2025-02-01 Minovia Therapeutics Ltd Mammalian cells are enriched with active mitochondria
US12551504B2 (en) * 2018-07-22 2026-02-17 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of pancreatic diseases
WO2020021536A1 (en) * 2018-07-22 2020-01-30 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy for primary mitochondrial diseases
JP7524157B2 (ja) * 2018-07-22 2024-07-29 ミノヴィア セラピューティクス リミテッド 脳疾患のミトコンドリア増強療法
JP7458368B2 (ja) * 2018-07-22 2024-03-29 ミノヴィア セラピューティクス リミテッド 筋疾患のミトコンドリア増強療法

Also Published As

Publication number Publication date
JP2023519744A (ja) 2023-05-12
IL296786A (en) 2022-11-01
CA3173425A1 (en) 2021-10-07
EP4125959A1 (en) 2023-02-08
JP7825866B2 (ja) 2026-03-09
AU2021248780A1 (en) 2022-11-10
WO2021199032A1 (en) 2021-10-07
CO2022013978A2 (es) 2022-10-31
EP4125959A4 (en) 2024-07-10
US20230338427A1 (en) 2023-10-26
KR20220161326A (ko) 2022-12-06
BR112022019432A2 (pt) 2022-12-06
MX2022012233A (es) 2023-03-08

Similar Documents

Publication Publication Date Title
JP7825866B2 (ja) ミトコンドリア増強療法
US20250101381A1 (en) Cells with increased immuno-regulatory properties and methods for their use and manufacture
Devine et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion
US12605410B2 (en) Mitochondria-enriched genetically engineered cells and uses thereof
US20220380727A1 (en) Generation of engineered regulatory t cells
CN112566645A (zh) 用于原发性线粒体疾病的线粒体增强疗法
JP2021532091A (ja) 膵臓疾患のミトコンドリア増強療法
CN112601532A (zh) 使用富集有功能性线粒体的干细胞的线粒体增强疗法
JP2021532095A (ja) 肝臓疾患のミトコンドリア増強療法
US20230392118A1 (en) Generation of cd4+ effector and regulatory t cells from human pluripotent stem cells
US20230392168A1 (en) Compositions and methods related to megakaryocyte-derived extracellular vesicles for treating myeloproliferative neoplasms
CN116396940A (zh) 造血干祖细胞及其制备方法和用途
US20220184137A1 (en) Correction of Beta-Thalassemia Phenotype by Genetically Engineered Hematopoietic Stem Cell
WO1998012304A1 (en) Culture system for hematopoietic stem cells
CN101083910B (zh) 用于预防和治疗移植中的免疫应答的肝脏基质细胞
JP2024546826A (ja) 骨髄異形成症候群のためのミトコンドリア増強療法
CN117015552A (zh) 用于治疗骨髓增殖性肿瘤的与巨核细胞来源的细胞外囊泡相关的组合物和方法
US20200263141A1 (en) Multi-Chimeric Cell and Therapy for Transplantation and Treatment of Immune Deficiencies and Genetic Disorders
HK40046349A (en) Cells with increased immuno-regulatory properties and methods for their use and manufacture
Horwitz Future Directions in Pediatric Stem-Cell Transplantation
MX2007008437A (es) Celulas estromales de medula osea para inmunoproteccion de celulas madre neurales transplantadas.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination